Allergan Faces Pipeline Setback on Rapastinel Clinical Failure
Allergan announced that its NMDA partial agonist, rapastinel, failed three of its phase 3 acute depression trials and is unlikely to meet its endpoints in a fourth trial for relapse prevention. Since we viewed rapastinel as one of the more promising products in the company’s pipeline, the announcement is another unfortunate setback for Allergan. Despite the disappointing news, we still think the current stock price undervalues the business and assumes a dire scenario for the company’s future. Wh...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.